Developing a new generation of TYK2 therapeutics


Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. The company’s pipeline of next generation TYK2 inhibitors includes a potential first- and best-in-class brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential first- and best-in-class topical candidate for immune-mediated dermatologic diseases.



World-class scientists and leaders in small molecule drug discovery and development.

Board of Directors



Developing a broad pipeline of best-in-class precision TYK2 inhibitors.

development pipeline

development pipeline

Targeting TYK2

Tyrosine kinase 2 (TYK2) is an enzyme that regulates immune and inflammatory signaling pathways by mediating the effects of cytokines such as IL-23, IL-12, and Type I interferons (IFNs). These cytokines are central to both innate and adaptive immune systems, including the functioning of Th17 and Th1 cells and the activity and polarization of cells with a myeloid lineage, e.g. macrophages and microglia. Inhibiting TYK2 has been shown to be beneficial in the treatment of psoriasis, psoriatic arthritis, and lupus (SLE). Compelling genetic evidence suggests that TYK2 inhibition could provide benefit in an even broader range of autoimmune conditions such as multiple sclerosis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and others. Emerging data has also established a role for TYK2 in mediating the underlying inflammatory processes involved in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Traditional approaches to inhibiting TYK2 and other Janus Kinase (JAK) family enzymes through binding in the catalytic kinase domain (JH1 domain) result in poorly selective binding and inhibition due to the nearly identical kinase domain structures shared among JAKs. This lack of selectivity in the inhibition of JAKs may result in safety issues that significantly limit the risk-benefit profile and therefore breadth of application for autoimmune and neurologic diseases.


Domain Structure of JAK-family Kinases

By allosterically regulating TYK2 kinase function through binding to the TYK2 pseudokinase domain (JH2 domain), significant improvement in selectivity versus other JAKs can be achieved. Increased selectivity provides the advantage of avoiding safety liabilities of agents known to inhibit JAK1 and/or JAK2, both peripherally and in the brain. Sudo Biosciences is developing multiple highly potent and selective small molecule TYK2 pseudokinase inhibitors designed to provide fit-for-purpose treatments across a broad range of autoimmune and neurologic conditions.


At Sudo Biosciences, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated inflammatory diseases.

We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the recruitment, training and career development of each team member at Sudo.

If you would like to be considered for a position at Sudo Biosciences, please submit your resume and cover letter to

Contact Us

Sudo Biosciences, Inc.
10401 N. Meridian St. | Suite 225 | Carmel, IN 46290